title: Active site-directed thrombin inhibitors: alpha-hydroxyacyl-prolyl-arginals, new orally active stable analogues of D-Phe-Pro-Arg-H.
abstract: D-alpha-Hydroxyacyl-prolyl-arginals, a new type of analogues of D-Phe-Pro-Arg-H (R1), have been prepared and evaluated. Unlike R1, whose terminal group is NH2, the new analogues with a terminal OH group are stable, as are the N-substituted derivatives of R1, that is, D-MePhe-Pro-Arg-H (R2), the highly potent and selective thrombin inhibitor, and Boc-D-Phe-Pro-Arg-H (R3), the much less favorable analogue. The most notable of the new analogues corresponds to the general formula D-Xaa-Pro-Arg-H, wherein Xaa means the acyl residue of mandelic acid (Man, 1), diphenyllactic acid (Dpl, 2), hexahydrophenyllactic acid (Hpl, 3), or hexahydromandelic acid (Hma, 4). In plasma clotting assays, 1 to 4 appeared to inhibit thrombin as well as some other clotting enzymes involved in thrombin generation, whereas R1 and R2 seemed to produce anticoagulation through inhibition of thrombin only. In the fibrin plate assay, 1 to 4 possessed even more moderate antifibrinolytic activities than R2. In in vivo evaluation in rats and rabbits, 2 to 4 proved to be potent anticoagulants/antithrombotics even on oral administration in a dose of 5 mg/kg. In view of these findings with the alpha-hydroxyacyl-prolyl-arginals, it is very likely that the less favorable biologic properties of Boc-D-Phe-Pro-Arg-H are due to the hydrophobicity and bulkiness of the terminal Boc-NH rather than its neutrality.
authors.affiliation: Institute for Drug Research, Budapest, Hungary.
authors.forename: S
authors.initials: S
authors.lastname: Bajusz
authors.forename: E
authors.initials: E
authors.lastname: Barabas
authors.forename: I
authors.initials: I
authors.lastname: Fauszt
authors.forename: A
authors.initials: A
authors.lastname: Feher
authors.forename: G
authors.initials: G
authors.lastname: Horvath
authors.forename: A
authors.initials: A
authors.lastname: Juhasz
authors.forename: G A
authors.initials: GA
authors.lastname: Szabo
authors.forename: E
authors.initials: E
authors.lastname: Szell
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000991:Antithrombins / Q000008:administration & dosage* / Q000302:isolation & purification; D001777:Blood Coagulation / Q000187:drug effects; D006801:Humans; D009842:Oligopeptides / Q000008:administration & dosage* / Q000302:isolation & purification / Q000494:pharmacology*; D011517:Prothrombin Time; D011817:Rabbits; D051381:Rats; D013918:Thrombin Time
chemical_list: D000991:Antithrombins; D009842:Oligopeptides; C035202:H-D-Phe-Pro-arginal